Senior Director, US Payer Medical Affairs & Outcomes Strategy

Overview

The Senior Director, US Payer Medical Affairs & Outcomes Strategy will report to the Vice President of US Medical Affairs, TTR and will have dual accountability across two core domains:

1. Medical Director Leadership (50%)- Lead the design and execution of the US Payer Ecosystem Medical Plan, including real-world evidence (RWE) strategy and collaborative pilots with payer organizations. Partner with internal and external stakeholders to generate meaningful insights that support patient access, value demonstration, and differentiation of Alnylam's portfolio.
2. Field Team Leadership (50%)- Oversee the US Payer Medical Outcomes Science Liaisons (MOSLs), ensuring strategic alignment and flawless execution of payer-focused initiatives. Provide coaching, mentoring, and performance management to optimize team impact across the managed care landscape.

This position is a US-Field based position.

Key Responsibilities

US Payer Medical Director Accountabilities (50%)

* Lead theUS Payer Ecosystem Medical Planin alignment with brand, evidence generation, and access strategies.

* Develop and implement areal-world payer evidence strategythat includes payer-driven research collaborations, pragmatic pilots, and data partnerships to address evidence needs for access and reimbursement.

* Serve as theprimary scientific and clinical point of contactfor US payer stakeholders, including PBMs, MCOs, IDNs, and state Medicaid programs.

* Collaborate with Health Economics & Outcomes Research (HEOR), Value & Access, and Policy teams to ensure payer evidence needs are incorporated into US and global evidence plans.

* Shape and leadstrategic payer-focused research collaborations, ensuring alignment with both scientific rigor and payer decision-making needs.

* Act as a thought leader inpayer-focused evidence generation, representing Alnylam in external forums and advancing partnerships with US healthcare systems.

US Payer MOSL Team Leadership (50%)

* Lead and manage theUS Payer MOSL organization, ensuring execution of strategy with excellence and consistency across regions.

* Translate payer evidence needs into actionableMOSL field engagement strategies, aligning account planning with corporate medical objectives.

* Providecoaching, development, and performance oversightfor MOSLs, fostering a culture of accountability, collaboration, and innovation.

* Partner closely with National Accounts, Market Access, and US Medical leadership to deliver an integrated field medical strategy across payer segments.

* Ensure strict compliance with all applicable PhRMA Codes, FDA laws, regulations, and company policies.

* Champion cross-functional collaboration to align payer field activities with corporate priorities and ensure seamless execution.

Qualifications

* 10+ years of experience inMedical Affairs, HEOR, or payer-focused functions within biopharma/healthcare.

*Required:Experienceeither at a US payer organization(e.g., MCO, PBM, Medicaid/Medicare, IDN)or within the pharmaceutical/biotech industry leading US payer medical and evidence strategy.

* Advanced degree in life sciences (MD, DO, PharmD, PhD) strongly preferred.

* Proven experience developing and executingpayer medical strategiesandreal-world evidence initiatives.

* Deep understanding of theUS payer landscape, including policy, access drivers, and evidence requirements.

* Demonstrated leadership experience managing field medical teams or payer-facing medical organizations.

* Excellent scientific communication skills with ability to engage credibly with payer medical directors, pharmacy directors, and value committees.

* Strong organizational and strategic planning skills, with a track record ofleading cross-functional initiatives.

* Ability to travel up to 50%.

About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.